- Top line: Total Q3 revenue was $2.99B, up ~23% YoY as membership expanded. MLR rose to 88.5% on higher market morbidity and risk‑adjustment accruals. SG&A ratio improved to 17.5% from 19.0%.
- Earnings vs. estimates:EPS of –$0.53 beat consensus (e.g., Refinitiv/Zacks ranges), while revenue missed expectations; management reaffirmed 2025 guidance.
- Outlook unchanged: FY25 revenue $12.0–$12.2B, MLR 86–87%, SG&A 17.1–17.6%, and loss from operations –$200M to –$300M.
- Capital move: On Nov. 5, the company exchanged $187.5M of 7.25% 2031 notes for ~23.27M shares, after entering an exchange agreement that allows up to $250M of notes to be exchanged by Dec. 14, 2025.
What happened in Q3
Oscar Health reported third‑quarter revenue of $2,985,984,000 (in thousands), up from $2,423,482,000 a year ago—about 23% YoY growth, driven largely by higher membership. The medical loss ratio (MLR) increased to 88.5% (from 84.6%), which the company tied to a $130M net risk‑adjustment transfer accrual reflecting higher average market morbidity; this was partly offset by $84M of favorable prior‑period development and $22M favorable intra‑year development. The SG&A expense ratio improved to 17.5% (from 19.0%), reflecting cost discipline and fixed‑cost leverage.
On the bottom line, Oscar posted a net loss of $137.5M (–$0.53/share) versus a $54.6M (–$0.22/share) loss a year ago. Loss from operations was $129.3M (vs. $48.4M), and Adjusted EBITDA was a loss of $101.5M. Total membership reached ~2.117M (vs. ~1.654M in Q3 2024), up roughly 28% year‑over‑year.
From a market‑reaction standpoint, third‑party coverage emphasized the EPS beat (e.g., –$0.53 vs. expectations around –$0.55) alongside a revenue miss (consensus ~$3.08–$3.14B).
Guidance: unchanged across key metrics
Management reaffirmed its full‑year 2025 outlook:
- Total revenue:$12.0B–$12.2B
- MLR:86.0%–87.0%
- SG&A ratio:17.1%–17.6%
- Loss from operations:–$200M to –$300M
This maintained guidance aligns broadly with external expectations (e.g., FactSet revenue near $12.0B).
On today’s call and in the release, leadership reiterated confidence in expanding margins and a return to profitability in 2026, with pricing and geographic expansion cited as contributors.
Balance sheet: convertible notes exchange simplifies capital structure
Beyond operating results, Oscar entered an exchange agreement (Nov. 3) with Oasis FD Holdings, L.P. (“Dragoneer”) permitting up to $250M of its 7.25% Convertible Senior Notes due 2031 to be exchanged by Dec. 14, 2025. On Nov. 5, $187.5M principal was exchanged for 23,273,179 shares of Class A common stock. The company notes this reduces future interest expense and removes certain covenants tied to the 2031 notes; however, it is dilutive to existing equity holders. SEC
(Background: the company also issued $355M of 2.25% convertible senior subordinated notes due 2030 in mid‑September, alongside capped calls; that financing context is relevant to its ongoing capital optimization.)
The market’s read—so far
Early coverage framed the quarter as a mixed print—EPS ahead, revenue behind—with the steady guidance and capital moves easing some concerns about funding costs heading into 2026.
Numbers at a glance (Q3 2025)
- Revenue:$2.99B (+~23% YoY)
- MLR:88.5% (+3.9 ppts YoY)
- SG&A ratio:17.5% (–1.5 ppts YoY)
- Net loss:$137.5M (–$0.53/share)
- Adj. EBITDA:–$101.5M
- Members:~2.117M (≈+28% YoY)
- FY25 guidance:Revenue $12.0–$12.2B; MLR 86–87%; SG&A 17.1–17.6%; Op. loss –$200M to –$300M.
What to watch next
- Open Enrollment dynamics: Marketplace enrollment trends and morbidity mix could influence MLR into Q4.
- Execution on cost discipline: The improved SG&A ratio will be a key proof point as scale builds.
- Further note exchanges: Whether Dragoneer exchanges the remaining authorization (~$62.5M) under the agreement before Dec. 14, 2025.
- Path to 2026 profitability: Watch margin cadence and any commentary on risk‑adjustment trends.
Sources
Press release and investor materials; SEC filings; and major wire services reporting on estimates and market reaction.
Disclosure: This article is for informational purposes only and is not investment advice.
